Difference between revisions of "Glucarpidase (Voraxaze)"
m (→References) |
|||
| Line 17: | Line 17: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Intravenous medications]] | ||
[[Category:Chemotherapy protective agents]] | [[Category:Chemotherapy protective agents]] | ||
[[Category:Drugs FDA approved in 2012]] | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 13:50, 6 August 2017
General information
Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found in the [https://www.btgplc.com/media/1213/voraxaze-prescribing-information-march-13-1.pdf Glucarpidase (Voraxaze) package insert[1]
- Glucarpidase (Voraxaze) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1/17/2012: Initial FDA approval "for the treatment of toxic plasma methotrexate concentrations (greater than 1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function."